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Inﬂammation has been recognized as an important hallmark of atherosclerosis. The pharmacological activation of PPAR-γ by the
thiazolidinediones in diabetes, and of PPAR-α by the ﬁbrates in hyperlipidemia has been shown to help to reduce inﬂammatory
markers in preclinical and clinical studies. PPARs are known to modulate immune pathways through at least three diﬀerent
mechanisms: by direct binding to PPRE of anti-inﬂammatory cytokines genes; by transrepression of transcription factors like
NF-κB and AP-1; or by corepression. The regulation of the inﬂammatory pathways by PPARs can be achieved on each one of the
cells involved in the atherosclerotic process, that is, monocytes, macrophages, T cells, endothelial cells, and smooth muscle cells.
Moreover, as each of these cellular components is interconnected with each other, PPAR activation in one cell type could aﬀect the
otherones.AsactivationofPPARshasclear ant-inﬂammatorybeneﬁts,PPARsligandsshouldbeconsideredasanewtherapeutical
approach to ameliorate the exacerbated immune response in atherosclerotic diseases.
Copyright © 2008 Ana Z. Fernandez. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Cardiovascular diseases represent the main cause of mor-
bidity and mortality in western societies since the 20th
century and mostly are a consequence of atherosclerosis,
a prior established pathology. Atherosclerosis is deﬁned
as a progressive, chronic pathology characterized by the
accumulation of lipids and ﬁbrous elements in the large
arteries. It is classiﬁed as an inﬂammatory disease, since
in every phase of the atherosclerotic process, the immune
response has a signiﬁcant role [1]. Immune cells like
monocytes, macrophages, and T-cells are crucial in the
development of the atheroma and the stimulation and
activation of endothelial cells (EC) and smooth muscle
cells (SMC), cellular components of the vascular wall are
extremelyrelevantfortherecruitmentofthecellsresponsible
for the immune response.
Peroxisome proliferator-activated receptors (PPAR) and
their agonists have been gaining more attention recently
in regard to the study of the mechanisms involved in the
etiology and pathogenesis of atherosclerosis. The expression
of PPAR-α,- δ/β,a n d- γ in vascular wall cells and in
immune cells, as well as in atherosclerotic lesions, has been
described [2, 3]. The pharmacological modulations of both
PPAR-α and -γ as therapeutic treatments for diabetes and
hyperlipidemia have been linked to an improvement on the
low-grade inﬂammation associated with these conditions
[4, 5]. The inhibition of function and/or expression of
certain genes critical for the initiation or maintenance
of inﬂammatory cells recruitment, survival, proliferation,
and activation has been shown to alter the progression of
atherosclerotic lesions [6]. In this regard, the three PPAR
isoforms certainly could play distinctive roles in modulating
the inﬂammatory response in atherosclerosis.
2. PPAR: GENERAL CHARACTERISTICS
The PPARs belong to a subfamily of the nuclear receptors
superfamily and are ligand-activated transcription factors
which heterodimerize with the retinoic X receptor and2 PPAR Research
recognize PPAR response elements (PPRE) localized in the
promoter region of target genes [2]. In addition to the
direct involvement of PPAR in the gene-speciﬁc transcrip-
tion, PPAR could also repress the transcription of certain
genes brought about by the proinﬂammatory transcription
factors, nuclear factor (NF)-κB, activation protein-1 (AP-
1), and signal transducer and activator of transcription 1
(STAT-1), through the binding and sequestration of their
corresponding cofactors [7].
Three PPAR forms have been described: PPAR-α
(NR1C1), PPAR-δ/β (NR1C2), and PPAR-γ (NR1C3). These
diﬀerent receptors show a similar protein structure in spite
of their diﬀerent coding genes [3]. PPAR-α and PPAR-γ
have been recognized to be key players in both cellular
diﬀerentiation processes and anti-inﬂammatory regulation
and, most recently, PPAR-δ/β has also been implicated in the
immune response [8].
PPAR-α is mainly expressed in tissues characterized by
a high rate of fatty acid catabolism (liver, kidney, heart,
and muscle) and is the most abundantly expressed PPAR
isoform in human endothelial cells (EC) [9]. The tran-
scriptional activity of PPAR-α is stimulated by a variety of
compounds (see Table 1)[ 2]. PPARα synthetic ligands, such
as cloﬁbrate, fenoﬁbrate, and bezaﬁbrate, were developed as
hypolipidemic agents, through optimization of their lipid-
lowering activity in rodents, even before the discovery of the
PPARs[10].PPAR-αisinvolvedinthecontroloflipoproteins
metabolism, fatty acid oxidation, and in the cellular uptake
of fatty acids [10]. Studies in vitro suggest that PPAR-α also
regulates the expression of genes that control inﬂammatory
responses in EC, SMC, and macrophages, cells known to be
implicated in the inﬂammatory response of vascular EC and
in the pathology of atherosclerosis [9, 11].
PPAR-δ/β is ubiquitously expressed both in vascular
SMC as well as in EC, besides liver, kidney, and abdominal
adipose tissues. Several eicosanoids have been reported to
activate PPAR-δ/β, including PGA1 and PGD2,a n das y n -
thetic prostaglandin carbaprostacyclin [10]. The important
physiologicalrolesofPPAR-δ/β arehighlightedingenetically
modiﬁed mouse models as deletion of PPAR-δ/β in mice
leads to incomplete but very high penetration of a lethal
phenotype and PPAR-δ/β heterozygous animals display
abnormal wound healing [12]. Additionally, PPAR-δ/β has
been implicated in the maintenance of lipid homeostasis
[13], keratinocyte proliferation in response to injury [12,
14, 15], hyperplasic development of adipose tissue in animal
under a high-fat diet [16], and was recently shown to have
beneﬁcial eﬀects on muscle fat oxidation and lipid proﬁles in
humans [17, 18].
The best characterized receptor in this group of nuclear
factors is the PPAR-γ which plays a signiﬁcant role in
adipocyte diﬀerentiation and fat deposition [10, 19]. This
receptor is expressed in adipose tissue, skeletal, and cardiac
muscle and is also expressed in human peripheral blood
monocytes and in monocytic cell lines. The large list of
activators of PPAR-γ includes prostaglandin-derived 15-
deoxi-delta 12,14PGJ2 (15d-PGJ2), the thiazolidinediones
(TZD) troglitazone (Rezulin
R), pioglitazone (ActosR), and
rosiglitazone (Avandia
R), among others (see Table 1)[ 2, 10,
20]. The currently marketed TZDs are potent and selective
PPAR-γ activators; they are antidiabetic agents that increase
the insulin sensitivity of target tissues in animal models
of non-insulin-dependent diabetes mellitus and in diabetic
patients.
One of the features that characterize the PPAR is the
large amounts of natural and synthetic molecules that
can activate them. PPARs are diﬀerentially activated by
naturally occurring eicosanoids and related molecules [21,
22]. Nitroalkene derivatives of fatty acids have also been
characterized as endogenous PPAR ligands. Schopfer et al.
[23], using CV-1 reporter cells cotransfected with plasmids
containing the ligand-binding domain for PPAR-α,- δ/β,a n d
-γ, found that nitrated linoleic acid (1μM) (LNO2)w a s
capable to induce signiﬁcant activation of PPAR-γ (620%),
PPAR-α (325%), and PPAR-δ/β (221%), when compared
to control cells. Concomitant works revealed the existence
of LNO2 and other fatty acid nitration products, generated
by NO-dependent reactions, in human red cells, blood, and
urine samples [24, 25].
The general approach used to study the eﬀects of PPARs
is through PPAR activation by natural or synthetic agonist.
However, PPAR ligands have been shown to have both
PPAR-dependent and -independent actions, which could
be addressed by in vivo genetic manipulation, such as
PPAR-knockout animals or in cell-based systems using small
interfering RNA [26].
3. INFLAMMATION IS MODULATED BY
Ox-LDL THROUGH PPAR
A primary initiating event in atherosclerosis is the accu-
mulation of modiﬁed low-density lipoprotein (LDL) in
the subendotelial matrix, such as oxidized-LDL (ox-LDL.
These ox-LDL are taken up by macrophages, inducing the
formation of foam cells, and stimulating the EC to produce
a number of proinﬂammatory molecules, such as monocyte
chemotactic protein (MCP)-1, whose eﬀects are mediated by
the G protein-coupled receptor CCR2, expressed mainly in
monocytes, basophils, and certain subsets of T cells [27, 28].
One of the most studied factors involved in the
atherosclerotic process is ox-LDL [29]. Ox-LDL pro-
vides ligands for PPAR-γ and PPAR-α [30, 31]a n d
also seems to enhance the expression of PPAR-γ in dif-
ferentiated macrophages [32]. Ox-LDL, oxidized linoleic
acid, and metabolites derived from it, including 9-
hydroxyoctadecaenoic acid (HODE) and 13-HODE, induce
PPAR-γ activation in monocytes and monocytic cellular
lines, stimulating the transcription of the ox-LDL receptor
CD36/fattyacidtranslocase,throughaPPREinthepromoter
of CD36/fatty acid translocase gene, which leads to the
formation of foam cells [19, 30, 33].
The ﬁrst contact between ox-LDL and monocyte/mac-
rophage cell elicits reactive oxygen species (ROS) formation,
followed by a desensitization of macrophages via activa-
tion of PPAR-γ, which reduces ROS production, giving
the ox-LDL a dual role in the activation/deactivation of
macrophages[34].Ox-LDLinhibitedNF-κB-mediatedIL-12Ana Z. Fernandez 3
Table 1: Properties and agonists of PPARs.
Characteristic PPAR-α PPAR-γ PPAR-δ/β
General distribution Liver, heart, kidney, muscle.
Endothelial cells
Heart, intestine, kidney,
pancreas, spleen, muscle,
adipose tissue
Liver, intestine, kidney,
abdominal adipose tissue,
skeletal muscle
Natural ligands
Saturated and unsaturated
fatty acids; arachidonic
acid-derived eicosanoids
from the lipoxygenase
pathway: 8-S-
hydroxyeicosatetraenoic
acid and leukotriene B4;
insulin; oxidized LDL
Linoleic acid, linolenic
acid, arachidonic acid,
eicosapentenoic acid,
15-deoxy Δ12,
14-prostaglandin J2;
15-LOX metabolites
(9-HODE and 13-HODE)
Saturated and unsaturated
fatty acids; eicosanoids:
PGA1 and PGD2
Synthetic agonists
Hypolipidemic ﬁbrate
drugs: fenoﬁbrate,
genﬁbrozil; plasticizers,
ureidoﬁbrates; WY14643,
JTT-501, GW-2331 and
PD72953
Antidiabetic
thiazolidinediones:
pioglitazone, troglitazone,
rosiglitazone (BRL-49653),
MCC-555;
isoxazolidinedione
JTT-501; tyrosine-based
agonist: GI2-62570,
GW-1929, and GW-7845
from GSK; α-alcoxy-β-
phenylpropanoic acid;
weak agonist: LTD4
receptor antagonist
LY-171883; COX inhibitors:
indomethacin, ibuprofen,
fenoprofen, and ﬂufenamic
acid. Docosohexanoic
derivatives
Leukotriene antagonist
L-165041; phenylacetic
derivatives L-796449 and
L-783483; GW-2433,
GW-501516, GW0742X;
carbaprostacyclin
Gene/protein expression
aﬀected
Lipoprotein lipase, Apo
CIII, Apo AI, Apo AII, fatty
acid transporter protein,
Acyl-CoA synthetase,
mitochondrial HMG-CoA
synthase, mitochondrial
uncoupling protein 1
Acyl-CoA synthetase, fatty
acid transporter protein,
CD 36, lipoprotein lipase,
TNF-α mitochondrial
uncoupling protein 1–3;
insulin-dependent glucose
transporter 4
Fatty acid transporter
protein, CD 36, fatty acid
translocase, adipocyte
lipid-binding protein,
ABCA1, 14-3-3ε
production in LPS-stimulated mouse macrophages, involv-
ing both inhibition of the NF-κB-DNA interactions and
physical interactions between NF-κB and PPAR-γ [35]. Acti-
vation of NF-κB is involved in the pathophysiology of many
inﬂammatory chronic diseases, including atherosclerosis.
Binding sites for NF-κB have been found in cellular adhesion
molecules and chemokines [36, 37]. The NF-κB signaling
pathway is activated by the proinﬂammatory cytokines TNF-
α and IL-1α which are the major cytokine inducers of gene
expression in EC. In resting macrophages, PPAR-γ ligands
completely blocked the ox-LDL-mediated activation of NF-
κB[ 38].
PPAR-α activation by ox-LDL in the vascular wall
components seems to upregulate the inﬂammation. The
activation of this receptor in human EC by oxidized com-
ponents in LDL resulted in an increase in the production
of chemotactic factors for monocytes (MCP-1 and IL-8),
conferring it a proinﬂammatory eﬀect [9].
4. MOLECULAR MECHANISMS FOR THE REGULATION
OF INFLAMMATORY/IMMUNE RESPONSE IN
ATHEROCLEROSIS BY PPAR AGONISTS
The adhesion of monocytes to the vascular wall is mediated
by adhesion molecules expressed on the surface of the
EC, such as vascular cell adhesion molecule-1 (VCAM-
1), intercellular adhesion molecule 1 (ICAM-1), P and E
selectins [39], which is a phenotypic hallmark of EC activa-
tion and a critical step of many proinﬂammatory processes.
The constitutive activation of PPAR-γ in ECs inhibited
the expression of VCAM-1, ICAM-1, and E-selectin, by
interference with NF-κB and AP-1 transactivation [40].
Many of the immune cells in the atheroma exhibit signs
of activation and produce proinﬂammatory cytokines. In
addition to monocytes and macrophages, T cells deﬁnitely
play a signiﬁcant role in the lesion, where CD4+ T cells
dominate over CD8+ cells. CD4+ T cells diﬀerentiate into4 PPAR Research
Table 2: PPAR-mediated immune downregulation in monocytes/macrophages, T cells, EC, and SMC.
Monocyte/macrophage T cell EC SMC
Reduced expression of
TNF-α, CCR-2, synthesis of
IL-6, IL-1 by PPAR-γ.
Oxidative burst suppressed
by PPAR-γ.
Reduced expression of
TNF-α,I F N - γ,I L - 2b y
activation of PPAR-γ and
-α.
Reduced expression of
VCAM-1, ICAM-1,
E-selectin and MHC-II by
PPAR-γ,- α, and -δ/β;
impaired TNF-α activation.
Reduced synthesis of IL6,
COX-2, and prostaglandin
by PPAR-α.
several subtypes, being T helper-1 cells (Th1) the predomi-
nant pattern in atherosclerosis. IFN-γ is a major proathero-
genic Th1 cytokine, promoting macrophage and endothelial
activationwithproductionofadhesionmolecules,cytokines,
chemokines, radicals, proteases, and coagulation factors. In
addition, IFN-γ inhibits cell proliferation, collagen pro-
duction, and cholesterol eﬄux [41]. PPAR-α and PPAR-γ
mRNA, and protein are expressed in isolated human CD4+
T cells, and the activation of each one of them by speciﬁc
ligands reduces the secretion of IFN-γ,T N F - α,a n dI L -
2 in these lymphocytes [42]. Furthermore, the eﬀect of
PPAR agonist on CD4+ T cells impaired their action on
monocytes and EC, suggesting that PPAR modulation of
inﬂammatory pathways in T cells may oﬀer clinical beneﬁts
in atherosclerosis [43].
TNFαisacatabolicproinﬂammatorycytokine,produced
by Th1 cells and macrophages, that exerts a wide range of
eﬀects on cells and tissues, through the activation of the
transcription factor NF-κB. Gene targeting of TNFα leads
to reduced atherosclerosis [42]. It has been shown that
human aortic EC activation by TNFα could be prevented by
incubation with MCC-555, a novel TZD, while pioglitazone
and rosiglitazone did not [44].
PPAR-α has been shown to inhibit transcriptional
responses to inﬂammatory stimuli by interfering with the
activation of NF-κB, leading to the reduction of VCAM-1
in EC [11]. In vascular SMC, PPAR-α agonists inhibited IL-
1-induced IL-6 expression, cyclooxygenase-2 (COX-2) and
prostaglandin production [45]. The upregulation of antioxi-
dant enzymes activity by the PPAR-α activators reduced the
oxidative stress and, as the result, it might inhibit the NF-κB
activation and subsequent inﬂammatory response [46].
The regulation of chemokine-receptor expression may
be a crucial mechanism to control monocyte responses to
chemokines. Monocytic-line THP-1 cells incubated with
rosiglitazone reduced CCR2 surface expression by about
50–60% (P < .001) compared with untreated control cells
[29]. PPAR-γ agonists suppress monocyte elaboration of
inﬂammatory cytokines TNFα,I L 1 ,a n dI L 6[ 47]. Table 2
summarizes the general eﬀects of PPAR activation on each
cell type.
In murine hypercholesterolemic models, the adminis-
tration of PPAR-γ ligands inhibited the development of
atherosclerosis, in spite of the high expression of CD36
in the vascular wall [48]. Downstream PPARγ-dependent
anti-inﬂammatory eﬀects of 15d-PGJ2 include the inhibition
of transcriptional activation by NF-κBv i aI κB, which
aﬀect gene expression of inducible nitric oxide synthase
(iNOS), TNFα,C O X - 2 ,I F N - α, IL-1, IL-6, and LPS-induced
transcription of AP-1 and STAT-1 [49]. Oxidative burst in
macrophages is also attenuated by PPAR-γ activation [50].
Other regulatory mechanism that could be attributed
to PPAR is the selective activation of anti-inﬂammatory
cytokines, like IL-10. IL-10 has potent deactivating prop-
erties in macrophages and T cells and modulates many
cellular processes that may interfere with the development
and stability of the atherosclerotic plaque [51]. Using
nanomolar concentrations of rosiglitazone, Thompson et al.
have demonstrated the upregulation of IL-10, likely through
a functional PPRE found in the promoter region of IL-10
gene [52].
Major histocompatibility complex class II molecules
(MHC-II) play a critical role in the induction of immune
responses by presenting peptides of foreign antigens to
CD4+ T lymphocytes, which result in their activation and
proliferation. Human ECs are capable of expressing MHC-II
under treatment with IFN-γ and this induction is repressed
by PPAR-γ ligands [53].
PPAR-δ/β s e e m st oh a v ed u a le ﬀects in regard to inﬂa-
mmation in atherosclerotic models [8, 54–57]. Although
results from both PPAR-δ/β–/– and PPAR-δ/β overex-
pressing macrophages suggested a proinﬂammatory role
for PPAR-δ/β, treatment of cells with PPAR-δ/β agonist
GW501516 suppressed the expression of MCP-1 and IL-1β
in a receptor-dependent manner, indicating that activation
of PPAR-δ/β had an anti-inﬂammatory eﬀect [54]. The
pharmacological modulation of PPAR-δ/β in atherosclerotic
LDLR–/– mice showed decreased expression of MCP-1,
TNFα, and ICAM-1 [55] and similarly, proinﬂammatory
modulators were suppressed in apoE–/– mice treated with
GW501516 [56]. Fan et al. also found an anti-inﬂammatory
eﬀect of PPAR-δ/β agonists in TNFα-activated EC [8]. In
addition, Takata et al. have found that PPAR-δ/β agonist
GW0742 substantially inhibited vascular proinﬂammatory
gene expression, macrophage content, and atherosclerosis in
an angiotensin II-induced high fat-fed male LDLR–/– mouse
model of accelerated atherosclerosis [57]. Furthermore,
promising results were obtained in a clinical evaluation
of the PPAR-δ/β agonist GW501516 in six obese males
[17]. Although inﬂammatory markers were not considered
in this study, the wide range of beneﬁcial eﬀects by the
pharmacological activation of PPAR-δ/β could suggest an
improvement on the inﬂammatory grade of proatherogenic
conditions and an attractive therapeutic target for drug
development to treat atherosclerosis [56].
Post-translational modiﬁcations have been found to
modulate transcriptional activity of PPAR-γ [57]. One of
these modiﬁcations is sumoylation, the covalent attachmentAna Z. Fernandez 5
of a small ubiquitin-like proteins (Ubl) called SUMO-1. Pas-
cual et al. [58] proposed a novel pathway mediating ligand-
dependent transrepression of inﬂammatory response genes
by PPAR-γ in macrophages which involves ligand-dependent
sumoylationofthePPAR-γ ligand-bindingdomain.Thistar-
gets PPAR-γ to nuclear receptor corepressor (NCoR)/histone
deacetylase-3 (HDAC3) complexes on inﬂammatory gene
promoters,whichinturnpreventsrecruitmentoftheubiqui-
tylation/19S proteosome machinery that normally mediates
the signal-dependent removal of corepressor complexes
required for gene activation. As a result, NCoR complexes
are not cleared from the promoter and target genes are
maintained in a repressed state. This mechanism provides
an explanation for how an agonist-bound nuclear receptor
can be converted from an activator of transcription to
a promoter-speciﬁc repressor of NF-κB target genes that
regulate immunity and homeostasis [59].
5. CONCLUSION
Basic and clinical research points out towards an intrinsic
interplay between immune/inﬂammatory mediators and
PPAR activation in the pathogenesis and development of
atherosclerosis. Each one of PPARs seems to have and share
diﬀerent output in order to reach the cellular homeostasis.
It could be seen that Inﬂammation, as a disruption of
homeostasis, has not only internal control by its own but
an external regulation through the activation of PPARs.
However, it is still not clear what are the “real functional
in vivo” natural ligands of PPAR. Meanwhile, the search for
the ideal synthetic ligand that would combine the beneﬁcial
eﬀects of PPAR activation is ongoing. Such “magical” drug
would be prescribed either as hypoglycemic, hypolipemic
and anti-inﬂammatory agent, but would need to be chron-
ically administered. Overall, pharmacological activation of
PPARs might be a better approach to cover all the underlying
inﬂammatory features of the atherosclerosis.
ABBREVIATIONS
ABC: ATP-binding cassette
ALBP: Adipocyte lipid binding protein
AP-1: Activation protein-1
COX: Cyclooxygenase
EC: Endothelial cells
FAT: Fatty acid translocase
HDAC3: Histone deacetylase-3
HDL: High-density lipoprotein
HMG-CoA: Hydroxy methyl glutaryl coenzyme A
HODE: Hydroxy octadecaenoic acid
ICAM-1: Intercellular adhesion molecule 1
IFN: Interferon
IL: Interleukin
LDL: Low-density lipoprotein
LNO2: Nitrated linoleic acid
LPS: Lipopolysaccharide
MCP: Monocyte chemotactic protein
MHC-II: Major histocompatibility complex class II
molecules (MHC-II)
NCoR: Nuclear receptor corepressor
NF-κB: Nuclear factor κB
NOS: Nitric oxide synthase
PG: Prostaglandin
PPAR: Peroxisome proliferator-activated receptors
PPRE: PPAR response elements
ROS: Reactive oxygen species
SMC: Smooth muscle cells
STAT-1: Signal transducer and activator of
transcription 1
Th: T helper cells
TNF: Tumor necrosis factor
TZD: Thiazolidinediones
Ubl: Ubiquitin-like proteins
VCAM-1: Vascular cell adhesion molecule-1.
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